

Projetos de investigação promovidos nos últimos dois anos

- Nome do projeto:** “Validación de una estrategia de prevención de infección en portadores de trasplante renal basada en un *bundle* individualizado de medidas y un score del grado neto de inmunosupresión”.

Nomes dos investigadores principais (IP, Co-IP,...): Francisco López-Medrano; Jose Maria Aguado

Entidade financiadora: Instituto de Salud Carlos III, Majadahonda, Comunidad de Madrid, Espanha (Organismo Público de Investigación)

Período de realização do projeto: 2017 - 2019

Financiamento: 21.175 €
- Nome do projeto:** “Utilidad de la monitorización de la viremia por allovirus como marcador subrogado del estado neto de inmunosupresión en receptores de trasplante renal”.

Nomes dos investigadores principais (IP, Co-IP,...): Mario Fernández-Ruiz; Jose Maria Aguado

Entidade financiadora: Instituto de Salud Carlos III, Majadahonda, Comunidad de Madrid, Espanha (Organismo Público de Investigación)

Período de realização do projeto: 2016 - 2018

Financiamento: 56.265 €
- Nome do projeto:** “Estudios de viabilidad de las innovaciones en salud”.

Nomes dos investigadores principais (IP, Co-IP,...): Francisco López-Medrano; Jose Maria Aguado

Entidade financiadora: Fundación para la Investigación y la prevención de SIDA

Período de realização do projeto: 01/2017 - 07/2017

Financiamento: 27.000 €
- Nome do projeto:** “Innovative strategies to seek novel biomarkers and predictive models in solid organ transplantation: establishing personalized transplant medicine”.

Nomes dos investigadores principais (IP, Co-IP,...): Jose Maria Aguado

Entidade financiadora: Proyecto Integrado de Excelencia en los Institutos de Investigación Acreditados. Instituto de Salud Carlos III, Majadahonda, Comunidad de Madrid, Espanha (Organismo Público de Investigación)

Período de realização do projeto: 01/2014 - 01/2017

Financiamento: 605.000 €
- Nome do projeto:** “Validación de un nuevo modelo de puntuación pronóstico basado en parámetros inmunológicos y virológicos como marcadores subrogados del estado neto de inmunosupresión en receptores de un trasplante de órgano sólido (SIMPLICITY-EBV)”.

Nomes dos investigadores principais (IP, Co-IP,...): Rafael San Juan Garrido; Jose Maria Aguado

Entidade financiadora: Instituto de Salud Carlos III, Majadahonda, Comunidad de Madrid, Espanha (Organismo Público de Investigación)

Período de realização do projeto: 2015 - 2017

Financiamento: 56.265 €

6. **Nome do projeto:** “Monitorización de la inmunidad celular específica frente a citomegalovirus en receptores de trasplante renal sometidos a tratamiento de la inducción con globulina policlonal anti-timocítica”.

Nomes dos investigadores principais (IP, Co-IP,...): Mario Fernández-Ruiz; Jose Maria Aguado

Entidade financiadora: Fundación Mutua Madrileña

Período de realização do projeto: 2014 - 2017

Financiamento: 26.000 €
7. **Nome do projeto:** “Efecto del tratamiento antiviral frente a citomegalovirus (CMV) en el desarrollo de enfermedad vascular del injerto en receptores de un trasplante cardiaco a través de la aplicación de los nuevos criterios coronariográficos de la ISHLT (International Society of Heart Transplantation).

Nomes dos investigadores principais (IP, Co-IP,...): Ana Garcia Reyne; Jose Maria Aguado

Entidade financiadora: Fundación Mutua Madrileña

Período de realização do projeto: 2013 - 2017

Financiamento: 38.000 €
8. **Nome do projeto:** “Ensayo clínico de comparación de una estrategia inmunoguiada frente a una estrategia guiada por viremia en la profilaxis de infección por CMV en receptores seropositivos de transplante”.

Nomes dos investigadores principais (IP, Co-IP,...): Jose Maria Aguado

Entidade financiadora: Instituto de Salud Carlos III, Majadahonda, Comunidad de Madrid, Espanha (Organismo Público de Investigación)

Período de realização do projeto: 2013 - 2017

Financiamento: 105.875 €
9. **Nome do projeto:** “Comparación de la eficacia y seguridad de una estrategia inmunoguiada frente a una estrategia guiada por viremia en la profilaxis de la infección por CMV en receptores seropositivos de TOS”.

Nomes dos investigadores principais (IP, Co-IP,...): Jose Maria Aguado; Rafael San Juan Garrido

Entidade financiadora: Fundación de Investigación Mutua Madrileña

Período de realización do projeto: 2012 - 2017

Financiamento: 13.000 €
10. **Nome do projeto:** “Ensayo clínico de comparación de una estrategia inmunoguiada frente a una estrategia guiada por viremia en la profilaxis de infección por CMV en receptores seropositivos de transplante”.

Nomes dos investigadores principais (IP, Co-IP,...): Jose Maria Aguado

Entidade financiadora: Instituto de Salud Carlos III, Majadahonda, Comunidad de Madrid, Espanha (Organismo Público de Investigación)

Período de realización do projeto: 2013 - 2016

Financiamento: 105.875 €

11. **Nome do projeto:** “Infecciones por Virus Influenza en receptores de trasplante: un registro multicéntrico”.

Nomes dos investigadores principais (IP, Co-IP,...): Francisco López Medrano; Jose Maria Aguado

Entidade financiadora: Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla

Período de realização do projeto: 2013 - 2016

Financiamento: 10.363 €

Publicações no ano de 2018

1. **Multidrug-resistant Gram-negative infection in solid organ transplant recipients: implications for outcome and treatment.** Silva JT, Fernández-Ruiz M, Aguado JM. *Curr Opin Infect Dis.* 2018 Oct 6. doi: 10.1097/QCO.0000000000000488. [Epub ahead of print]. PMID: 30299353.
2. **Highlights in solid transplant infectious diseases 2015-2017.** Tiago Silva J, López-Medrano F, Aguado JM. *Rev Esp Quimioter.* 2018 Sep;31 Suppl 1:52-55. Review. PMID: 30209925
3. **Viral infections in the biologic therapy era.** Noreña I, Fernández-Ruiz M, Aguado JM. *Expert Rev Anti Infect Ther.* 2018 Sep 8:1-11. doi: 10.1080/14787210.2018.1521270. [Epub ahead of print]. PMID: 30198355
4. **Vitamin D deficiency and infection risk in kidney transplant recipients: A single-center cohort study.** Fernández-Ruiz M, Corbella L, Morales-Cartagena A, González E, Polanco N, Ruiz-Merlo T, Parra P, Silva JT, López-Medrano F, San Juan R, Aramendi M, Andrés A, Aguado JM. *Transpl Infect Dis.* 2018 Sep 5:e12988. doi: 10.1111/tid.12988. [Epub ahead of print]. PMID: 30187601
5. **Executive summary of clinical practice guideline for the management of invasive diseases caused by *Aspergillus*: 2018 Update by the GEMICOMED-SEIMC/REIPI.** Garcia-Vidal C, Alastruey-Izquierdo A, Aguilar-Guisado M, Carratalà J, Castro C, Fernández-Ruiz M, Aguado JM, Fernández JM, Fortún J, Garnacho-Montero J, Gavalda J, Gudiol C, Guinea J, Gómez-López A, Muñoz P, Pemán J, Rovira M, Ruiz-Camps I, Cuenca-Estrella M. *Enferm Infecc Microbiol Clin.* 2018 Jun 27. pii: S0213-005X(18)30200-3. doi: 10.1016/j.eimc.2018.03.018. [Epub ahead of print] English, Spanish. PMID: 29960829.
6. **Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.** Fernández-Ruiz M, Giménez E, Vinuesa V, Ruiz-Merlo T, Parra P, Amat P, Montejo M, Paez-Vega A, Cantisán S, Torre-Cisneros J, Fortún J, Andrés A, San Juan R, López-Medrano F, Navarro D, Aguado JM; Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). *Clin Microbiol Infect.* 2018 May 25. pii: S1198-743X(18)30441-5. doi: 10.1016/j.cmi.2018.05.010. [Epub ahead of print]. PMID: 29803844
7. **Current approaches to visceral leishmaniasis treatment in solid organ transplant recipients.** Clemente WT, Mourão PHO, Aguado JM. *Expert Rev Anti Infect Ther.* 2018 May;16(5):391-397. doi: 10.1080/14787210.2018.1473763. Epub 2018 May 8. PMID: 29737887.
8. **Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe.** Coussement J, Maggiore U, Manuel O, Scemla A, López-Medrano F, Nagler EV, Aguado JM, Abramowicz D; European Renal Association-European Dialysis Transplant Association (ERA-EDTA) Developing Education Science and

Care for Renal Transplantation in European States (DESCARTES) working group and the European Study Group for Infections in Compromised Hosts (ESGICH) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). *Nephrol Dial Transplant*. 2018 Apr 9. doi: 10.1093/ndt/gfy078. [Epub ahead of print]. PMID: 29635410.

9. **T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study.** Muñoz P, Vena A, Machado M, Martínez-Jiménez MC, Gioia F, Gómez E, Origüen J, Orellana MÁ, López-Medrano F, Pérez-Granda MJ, Aguado JM, Fortún J, Bouza E; T2MadRid study group. *J Antimicrob Chemother*. 2018 Mar 1;73(suppl_4):iv13-iv19. doi: 10.1093/jac/dky048. PMID: 29608752.
10. **T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study.** Muñoz P, Vena A, Machado M, Gioia F, Martínez-Jiménez MC, Gómez E, Origüen J, Orellana MÁ, López-Medrano F, Fernández-Ruiz M, Merino P, González-Romo F, Frías I, Pérez-Granda MJ, Aguado JM, Fortún J, Bouza E; T2MadRid study group. *J Antimicrob Chemother*. 2018 Mar 1;73(suppl_4):iv6-iv12. doi: 10.1093/jac/dky047. PMID: 29608751
11. **Post-transplant hypocomplementemia: A novel marker of cardiovascular risk in kidney transplant recipients?** Maestro de la Calle G, Fernández-Ruiz M, López-Medrano F, Polanco N, González E, San Juan R, Ruiz-Merlo T, Origüen J, Paz-Artal E, Andrés A, Aguado JM. *Atherosclerosis*. 2018 Feb;269:204-210. doi: 10.1016/j.atherosclerosis.2018.01.021. Epub 2018 Jan 27. PMID: 29407595
12. **Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America.** Clemente WT, Pierrotti LC, Abdala E, Morris MI, Azevedo LS, López-Vélez R, Cuenca-Estrella M, Torre-Cisneros J, Petersen E, Camargo LFA, Wright AJ, Beeching NJ, Vilela EG, Santoro-Lopes G, Len O, Stucchi RSB, Manuel O, Faria LC, Leblebicioglu H, Huprikar S, Molina I, Mourão PHO, Kotton CN, Aguado JM; working group on Endemic Disease and Travel Medicine in Solid-Organ Transplantation. *Transplantation*. 2018 Feb;102(2):193-208. doi: 10.1097/TP.0000000000002027. Review. PMID: 29381647
13. **ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).** Reinwald M, Silva JT, Mueller NJ, Fortún J, Garzoni C, de Fijter JW, Fernández-Ruiz M, Grossi P, Aguado JM. *Clin Microbiol Infect*. 2018 Jun;24 Suppl 2:S53-S70. doi: 10.1016/j.cmi.2018.02.009. Epub 2018 Feb 16. Review. PMID: 29454849
14. **ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).** Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M. *Clin Microbiol Infect*. 2018 Jun;24 Suppl 2:S21-S40. doi: 10.1016/j.cmi.2018.02.002. Epub 2018 Feb 12. Review. PMID: 29447987

15. **ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).** Redelman-Sidi G, Michielin O, Cervera C, Ribí C, Aguado JM, Fernández-Ruiz M, Manuel O. *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S95-S107. doi: 10.1016/j.cmi.2018.01.030. Epub 2018 Feb 7. Review. PMID: 29427804
16. **ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction).** Fernández-Ruiz M, Meije Y, Manuel O, Akan H, Carratalà J, Aguado JM, Delaloye J. *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S2-S9. doi: 10.1016/j.cmi.2018.01.029. Epub 2018 Feb 7. Review. PMID: 29427801
17. **Tuberculosis Recommendations for Solid Organ Transplant Recipients and Donors.** Santoro-Lopes G, Subramanian AK, Molina I, Aguado JM, Rabagliatti R, Len O. *Transplantation.* 2018 Feb;102(2S Suppl 2):S60-S65. doi: 10.1097/TP.0000000000002014. No abstract available. PMID: 29381579
18. **Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study.** Fernández-Ruiz M, Polanco N, García-Santiago A, Muñoz R, Hernández AM, González E, Mercado VR, Fernández I, Aguado JM, Praga M, Andrés A. *Transpl Int.* 2018 Aug;31(8):887-899. doi: 10.1111/tri.13118. Epub 2018 Feb 5. PMID: 29356211.
19. **Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.** Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group. *Lancet Infect Dis.* 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19. PMID: 29273269
20. **Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature.** Silva JT, Pérez-González V, Lopez-Medrano F, Alonso-Moralejo R, Fernández-Ruiz M, San-Juan R, Brañas P, Folgueira MD, Aguado JM, de Pablo-Gafas A. *Clin Transplant.* 2018 Feb;32(2). doi: 10.1111/ctr.13176. Epub 2017 Dec 26. PMID: 29226391
21. **Association between baseline serum hepcidin levels and infection in kidney transplant recipients: Potential role for iron overload.** Fernández-Ruiz M, Parra P, Ruiz-Merlo T, López-Medrano F, San Juan R, Polanco N, González E, Andrés A, Aguado JM. *Transpl Infect Dis.* 2018 Feb;20(1). doi: 10.1111/tid.12807. Epub 2018 Jan 10. PMID: 29120522
22. **Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey.** Navarro D, San-Juan R, Manuel O, Giménez E, Fernández-Ruiz M, Hirsch HH, Grossi PA, Aguado JM;

ESGICH CMV Survey Study Group, on behalf of the European Study Group of Infections in Compromised Hosts (ESGICH) from the Society of Clinical Microbiology and Infectious Diseases (ESCMID). *Transpl Infect Dis*. 2017 Dec;19(6). doi: 10.1111/tid.12773. Epub 2017 Oct 25. PMID: 28859257

23. **Comparison of the clinical course of *Clostridium difficile* infection in glutamate dehydrogenase-positive toxin-negative patients diagnosed by PCR to those with a positive toxin test.** Origüen J, Corbella L, Orellana MÁ, Fernández-Ruiz M, López-Medrano F, San Juan R, Lizasoain M, Ruiz-Merlo T, Morales-Cartagena A, Maestro G, Parra P, Villa J, Delgado R, Aguado JM. *Clin Microbiol Infect*. 2018 Apr;24(4):414-421. doi: 10.1016/j.cmi.2017.07.033. Epub 2017 Aug 12. PMID: 28811244
24. **Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.** Aguado JM, Silva JT, Fernández-Ruiz M, Cordero E, Fortún J, Gudíol C, Martínez-Martínez L, Vidal E, Almenar L, Almirante B, Cantón R, Carratalá J, Caston JJ, Cercenado E, Cervera C, Cisneros JM, Crespo-Leiro MG, Cuervas-Mons V, Elizalde-Fernández J, Fariñas MC, Gavaldà J, Goyanes MJ, Gutiérrez-Gutiérrez B, Hernández D, Len O, López-Andujar R, López-Medrano F, Martín-Dávila P, Montejo M, Moreno A, Oliver A, Pascual A, Pérez-Nadales E, Román-Broto A, San Juan R, Serón D, Solé-Jover A, Valerio M, Muñoz P, Torre-Cisneros J; Spanish Society of Transplantation (SET); Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC); Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016). *Transplant Rev (Orlando)*. 2018 Jan;32(1):36-57. doi: 10.1016/j.trre.2017.07.001. Epub 2017 Jul 26. Review. PMID: 28811074
25. **Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation.** López-Medrano F, Fernández-Ruiz M, Silva JT, Carver PL, van Delden C, Merino E, Pérez-Saez MJ, Montero M, Coussement J, de Abreu Mazzolin M, Cervera C, Santos L, Sabé N, Scemla A, Cordero E, Cruzado-Vega L, Martín-Moreno PL, Len Ó, Rudas E, Ponce de León A, Arriola M, Lauzurica R, David MD, González-Rico C, Henríquez-Palop F, Fortún J, Nucci M, Manuel O, Paño-Pardo JR, Montejo M, Vena A, Sánchez-Sobrinó B, Mazuecos A, Pascual J, Horcajada JP, Lecompte T, Moreno A, Carratalà J, Blanes M, Hernández D, Hernández-Méndez EA, Fariñas MC, Perelló-Carrascosa M, Muñoz P, Andrés A, Aguado JM; Spanish Network for Research in Infectious Diseases (REIPI); Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC); Study Group for Infections in Compromised Hosts (ESGICH) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Swiss Transplant Cohort Study (STCS). *Clin Microbiol Infect*. 2018 Feb;24(2):192-198. doi: 10.1016/j.cmi.2017.06.016. Epub 2017 Jun 23. PMID: 28652112.